Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Company Overview

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Key Stats

• Today's Range: $5.75 to $5.92
• 50-Day Range: $3.05 to $5.89
• 52-Week Range: $1.14 to $7.20
• Volume: 521,675 shs
• Average Volume: 927,464 shs
• Market Capitalization: $352.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Moderate Buy

Aldeyra Therapeutics Stock Analysis - MarketRank™

Aldeyra Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 746th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aldeyra Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Aldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aldeyra Therapeutics is -6.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aldeyra Therapeutics is -6.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aldeyra Therapeutics has a P/B Ratio of 6.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.29% of the float of Aldeyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently increased by 8.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aldeyra Therapeutics does not currently pay a dividend.

Dividend Growth

Aldeyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.29% of the float of Aldeyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently increased by 8.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.77

News Sentiment

Aldeyra Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Aldeyra Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aldeyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $113,676.00 in company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Aldeyra Therapeutics is held by insiders.

Percentage Held by Institutions

59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALDX Stock Analysis - Frequently Asked Questions

How have ALDX shares performed this year?

Aldeyra Therapeutics' stock was trading at $4.99 on January 1st, 2025. Since then, ALDX stock has increased by 18.0% and is now trading at $5.89.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) posted its quarterly earnings results on Thursday, August, 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05.

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' top institutional investors include Perceptive Advisors LLC (6.76%), Ardsley Advisory Partners LP (3.42%), AQR Capital Management LLC (2.46%) and Geode Capital Management LLC (1.91%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Stephen Machatha, Bruce Greenberg and Nancy Miller-Rich.
View institutional ownership trends.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/26/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALDX
• CIK: 1341235
• Web: www.ampliphibio.com
• Phone: 781-761-4904
• Fax: 781-270-0630
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aldeyra Therapeutics: $9.50
• High Price Target: $10.00
• Low Price Target: $9.00
• Potential Upside/Downside: +61.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.63%
• Return on Assets: -50.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.86
• Quick Ratio: 2.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.19 per share
• Price / Book: 4.95

Miscellaneous

• Outstanding Shares: 59,900,000
• Free Float: 54,805,000
• Market Cap: $352.81 million
• Optionable: Optionable
• Beta: 0.76